

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/000,333	10/22/2001	Lisa P. Weinberg	A01P1078	9773
36802	7590 10/04/2004		EXAMINER	
PACESETTE		<i>V</i> .	GETZOW, SCOTT M	
15900 VALLEY VIEW COURT SYLMAR, CA 91392-9221			ART UNIT	PAPER NUMBER
			3762	.()
	·		DATE MAILED: 10/04/2004	4 (U

Please find below and/or attached an Office communication concerning this application or proceeding.

			_
	Application No.	Applicant(s)	
	10/000,333	WEINBERG ET AL.	
Office Action Summary	Examiner	Art Unit	-
	Scott M. Getzow	3762	_
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet w	th the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a relif NO period for reply is specified above, the maximum statutory perions are provided by the second period for reply will, by state than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	I.  1.136(a). In no event, however, may a reply within the statutory minimum of thir by will apply and will expire SIX (6) MON ute, cause the application to become A	eply be timely filed by (30) days will be considered timely. ITHS from the mailing date of this communication. SANDONED (35 U.S.C. § 133).	
Status			
1)    Responsive to communication(s) filed on <u>26</u> 2a)    This action is <b>FINAL</b> .    2b)    The solution is the condition for allow closed in accordance with the practice under	nis action is non-final.  vance except for formal matt		
Disposition of Claims			
4) ⊠ Claim(s) <u>1-33</u> is/are pending in the application 4a) Of the above claim(s) is/are withdrest 5) ⊠ Claim(s) <u>1-15</u> is/are allowed.  6) ⊠ Claim(s) <u>16-33</u> is/are rejected.  7) □ Claim(s) is/are objected to.  8) □ Claim(s) are subject to restriction and	rawn from consideration.		
Application Papers			
9) The specification is objected to by the Exami 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the	ccepted or b) objected to ne drawing(s) be held in abeyarection is required if the drawing	nce. See 37 CFR 1.85(a). (s) is objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority application from the International Bure * See the attached detailed Office action for a life.	ents have been received. ents have been received in A riority documents have been eau (PCT Rule 17.2(a)).	application No received in this National Stage	
Attachment(s)  1) X Notice of References Cited (PTO-892)	4) Interview	Summary (PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/C Paper No(s)/Mail Date	Paper No(	s)/Mail Date nformal Patent Application (PTO-152)	

Application/Control Number: 10/000,333

Art Unit: 3762

?

## Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claims 16,17,19,22,23 are rejected under 35 U.S.C. 102(b) as being anticipated by Hill et al (6006134).

Figures 16-19 show a transvenous lead that has an insulating sheath, and at least one conductor connected to a proximal connector. Column 2, lines 60-67 teach that the transvenous leads are meant to be located in a vein adjacent nerve fibers to be stimulated, and that the invention can be part of an implantable stimulator device. Column 8, line 21 teaches that the catheter can be used in the azygos vein, and lines 6+ teach that stimulating the right vagal nerve to reduce heart rate is known in the art. Column 7, lines 22+ teach that the catheter can be used in the SVC. Column 9, line 24 teaches that a preformed bend can be made in the lead to properly position the lead for vagal stimulation. Thus, the Hill device teaches all of the structure of the above claims. For the lead to make contact with tissue proximate to the cardiac branch of the right vagus nerve is considered to be implicitly accomplished, or capable of being accomplished, by the lead of Hill. Further, the placement is considered to be intended use that relates to the method of using the lead.

Application/Control Number: 10/000,333

Art Unit: 3762

## Claim Rejections - 35 USC § 103

3. Claims 20,21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hill et al in view of Dahl et al (6697677).

To use an expandable basket type electrode array, as shown by Dahl (see figures 11,12), would have been obvious since such is known in the art to provide secure contact with the walls of the vascular system of a patient.

4. Claims 18,24-28,31-33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hill et al in view of Warman et al (6201994).

Warman teaches a single pass lead with electrodes in the SVC, coronary sinus, atrium, and ventricle. It would have been obvious to use to use a single lead, as shown by Warman, since such would reduce the complexity of the device, as well as cost. As mentioned above, Hill teaches an implantable device that contains a vagal module used for vagal stimulation. Hill also teaches the use of atrial and ventricular electrodes, see figure 16. Hill also teaches that an electrode can be used in the SVC. The structure of the above combination could deliver stimulation pulses to the atrium, if so desired, and thus encompasses the functional language of the claim 27. Regarding claim 18, Warman shows arms 272 in figure 9. The ordinarily skilled artisan would realize that such arms could be used to be inserted in a nearby vessel.

Application/Control Number: 10/000,333

Art Unit: 3762

5. Claims 29,30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hill et al and Warman et al and further in view of Dahl.

It would have been obvious to use the expandable electrode of Dahl for reasons mentioned supra.

Since new rejections have been made, this action is not made final.

## Allowable Subject Matter

6. Claims 1-15 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Scott M. Getzow whose telephone number is (703) 308-2997. The examiner can normally be reached on M-F, 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on (703) 308-5181. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Scott M. Getzow Primary Examiner Art Unit 3762

Smg